Chitosan-covered calcium phosphate particles as a drug vehicle fordelivery to the eyeстатья
Статья опубликована в высокорейтинговом журнале
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 4 марта 2022 г.
Аннотация:E.V. Popova, V.E. Tikhomirova, O.V. Beznos, N.B. Chesnokova, Y.V. Grigoriev, N.L. Klyachko, O.A. Kost (2022). Chitosan-covered calcium phosphate particles as a drug vehicle fordelivery to the eye. Nanomedicine: Nanotechnology, Biology, and Medicine. V. 40 (February 2022). Art N.102493. P.1-10. https://doi.org/10.1016/j.nano.2021.102493ISSN: 1549-9634IF 6.458 (Q1)Formulations on the base of an inhibitor of angiotensin-converting enzyme, enalaprilat, were prepared by the inclusion of the drug into calcium phosphate (CaP)-particles in situ, followed by the covering of the particles with 5 kDa chitosan or 72 kDa glycol chitosan and cross- linking with sodium tripolyphosphate. Physicochemical characterization of the resulted hybrid particles was conducted using dynamic light scattering, as well as scanning and transmission electron microscopy. Enalaprilat-containing particles had a mean hydrodynamic diameter 180 nm and 260 nm and ζ-potential +7 mV and +16 mV for 5 kDa and 72 kDa chitosans, respectively. In vivo studies showed that enalaprilat within particles stayed longer in the tear fluid after single instillation and caused a significantly pronounced and prolonged decrease of intraocular pressure in rabbits, especially in the case of CaP-particles, covered by glycol chitosan. Thus, such formulations demonstrate potential as prospective therapeutic agents for the treatment of eye diseases.